GSK Strengthens ADC Portfolio with $1 Billion Deal with DualityBio for GI Cancer Focus

GSK has entered into a strategic alliance with DualityBio to strengthen its antibody-drug conjugate (ADC) portfolio with a deal potentially worth $1 billion[1][2]. This collaboration gives GSK an exclusive option to license the ADC known as DB-1324, which targets gastrointestinal cancer, a disease responsible for a substantial portion of cancer-related deaths worldwide[1]. The agreement includes an upfront payment of $30 million and entitles GSK to additional payments up to $975 million upon achieving certain milestones[2]. This alliance further highlights GSK's focus on expanding its oncology pipeline and capitalizing on global expertise[1].